bearish
Dechra Pharmaceuticals (DPH LN): Best Case Scenario Offers 10% Upside Potential
390 Views21 Apr 2023 17:47
SUMMARY
- Dechra Pharmaceuticals (DPH LN) received an offer from the Swedish private equity firm EQT regarding a possible all-cash deal, where Dechra shareholders would receive £40.70 per ordinary share in cash.
- Right after the announcement, Dechra shares surged 33%. The shares are currently trading at £37.66, implying 10% upside potential.
- Without EQT offer, based on current financial performance, Dechra has a bleak outlook. Currently, Dechra has average target price of £39.39, implying a spread of just ~5%.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
- EQT/Dechra Pharmaceuticals: Recommended Offer02 Jun 2023
- EQT/Dechra Pharmaceuticals: Generous Possible Offer27 Apr 2023
- Dechra Pharmaceuticals (DPH LN): Best Case Scenario Offers 10% Upside Potential21 Apr 2023
- Dechra Pharmaceuticals (DPH LN): Recent Sell-Off Is a Buying Opportunity; Fundamentals Remain Intact17 Feb 2022
- Dechra Pharmaceuticals (DPH LN): A High-Quality Idea in Companion Animal Healthcare Space12 Nov 2021
x